HMGB1 and infection: Based on the hypothesis that HMGB1 released during infection contributes to disease pathogenesis, the therapeutic efficacy of an HMGB1 neutralizing monoclonal antibody (2G7) was investigated in ECM-susceptible mice, at a dose previously shown to confer protection in experimental sepsis models[8].